ADALTA LIMITED — AGM Information 2020

Nov 22, 2020

==> picture [539 x 74] intentionally omitted <==

23 November 2020

ASX Announcement

2020 ANNUAL GENERAL MEETING REMINDER

MELBOURNE Australia, 23 November 2020: AdAlta Limited (ASX:1AD) wishes to remind shareholders that the Company’s Annual General Meeting (AGM) will be held on Wednesday 25 November 2020 at 11:00am AEDT.

As previously communicated to shareholders, in light of current public health restrictions relating to the spread of COVID-19 the 2020 AGM is a fully virtual meeting.

Following the AGM’s formal business, CEO and Managing Director Dr Tim Oldham will provide a Company update to shareholders.

If you wish to attend the virtual AGM, please register via the link below:

• • https://us02web.zoom.us/webinar/register/WN_my7oiXp RJu5ja4X Q_mQQ

Should you be eligible to vote, wish to vote on any resolution at the AGM and have not lodged a valid proxy form, please complete an additional registration to vote in accordance with the Virtual Meeting Voting and Registration guide (included in this announcement) via the link below:

https://investor.automic.com.au/#/home

Authorised for lodgement by:

Tim Oldham CEO and Managing Director November 2020

==> picture [595 x 83] intentionally omitted <==

==> picture [539 x 74] intentionally omitted <==

Notes to Editors About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today’s most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is conducting a Phase 1 clinical trial for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with multi-national company GE Healthcare for discovery of a diagnostic imaging agent against Granzyme B for use in immunooncology.

AdAlta’s strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Media

Tim Oldham, CEO & Managing Director IR Department Tel: +61 403 446 665 Tel: +61 411 364 382 E: t.oldham@adalta.com.au E: gabriella.hold@irdepartment.com.au

==> picture [595 x 83] intentionally omitted <==

Virtual Meeting Registration and Voting

==> picture [540 x 39] intentionally omitted <==

REGISTRATION

• Go to: https://investor.automic.com.au/#/home.

• Log in using your existing username and password or click on “register” and follow the on-screen prompts to create your login credentials.

==> picture [421 x 175] intentionally omitted <==

• Once logged in you will see that the meeting is open for registration. Click on “view”.

==> picture [418 x 113] intentionally omitted <==

• Click on “register” to register your attendance for the meeting.

==> picture [390 x 146] intentionally omitted <==

==> picture [540 x 39] intentionally omitted <==

REGISTRATION

• Select “yes, I would like to vote” and then click “next”.

==> picture [386 x 222] intentionally omitted <==

• You will be placed on a holding page until voting opens for the meeting. From here you can access the meeting video/audio by selecting the meeting URL.

• Once the Chair of the Meeting declares voting open, you should select “refresh”.

==> picture [385 x 226] intentionally omitted <==

==> picture [540 x 39] intentionally omitted <==

VOTING

• The next screen will display the resolutions to be put to the meeting.

• The Chair of the meeting will provide instructions on when to mark your vote.

• You record your vote by selecting either “for”, “against” or “abstain” next to the appropriate resolution.

• Once voting has been declared closed you must select “next” to submit your vote.

==> picture [380 x 274] intentionally omitted <==

• On the next screen, check your vote is correct and select the box next to “declaration” – you cannot confirm your vote unless you select this box.

• • Select “confirm” to confirm your vote – you CANNOT amend your vote after pressing the “confirm” button.

==> picture [323 x 161] intentionally omitted <==

==> picture [540 x 39] intentionally omitted <==

VOTING COMPLETE

• Your vote is now lodged and is final.

==> picture [435 x 251] intentionally omitted <==

==> picture [540 x 39] intentionally omitted <==